Home / Journals Pharmaceutical Science and Technology / Vaccines to Combat Malaria
Vaccines to Combat Malaria
Submission Deadline: Jan. 30, 2017
Lead Guest Editor
Jill Shukla
Department of Pharmaceutics, Gujarat Technological University, bardoli, Gujarat, India
Guest Editor
Guest Editors play a significant role in a special issue. They maintain the quality of published research and enhance the special issue’s impact. If you would like to be a Guest Editor or recommend a colleague as a Guest Editor of this special issue, please Click here to fulfill the Guest Editor application.
Guidelines for Submission
Manuscripts can be submitted until the expiry of the deadline. Submissions must be previously unpublished and may not be under consideration elsewhere.
Papers should be formatted according to the guidelines for authors (see: http://www.sciencepublishinggroup.com/journal/guideforauthors?journalid=515). By submitting your manuscripts to the special issue, you are acknowledging that you accept the rules established for publication of manuscripts, including agreement to pay the Article Processing Charges for the manuscripts. Manuscripts should be submitted electronically through the online manuscript submission system at http://www.sciencepublishinggroup.com/login. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal and will be listed together on the special issue website.
Published Papers
The special issue currently is open for paper submission. Potential authors are humbly requested to submit an electronic copy of their complete manuscript by clicking here.
Malaria continues to pose a tremendous public health burden for people living in the tropical region, particularly in Asian and African countries. Globally, approximately 300 to 500 million people are infected annually, which is more than 40% of the global population and it causes more than 2 million deaths each year. Malarial parasites have complex life cycles and distinct developmental stages, each of which has multiple antigens that could serve as targets of an immune response. A pre erythrocytic vaccine would protect against the infectious form injected by a sporozoite and/ or inhibit parasite development in the liver. An erythrocytic or blood stage vaccine would inhibit would inhibit parasite multiplication in the red cells, thus preventing or diminishing severe disease during blood infection. An optimal vaccine would have the ability to elicit protective immunity that blocks infection as well as prevents pathology and interrupt stransmission of parasites. To date most effort of vaccines development has focused on p. falciparum for the reasons like: High mortality from infection, capability for experimental challenges, relative ease of in-vitro studies and availability of animal models for in-vivo studies. Some important achievements have been made in past few years, which will contribute significantly to malaria control. They include exploitation of p. falciparum, A. gambiae and human genomes. Also, development of new drugs, new vaccine candidates, development and implementation of combinational therapies, intermittent preventive treatment and home management of malaria. These challenges will only be alleviated, and control strategies achieve maximum impact, if additional resources are deployed to strengthen malaria research and control communities in countries where the new tools will be used. Continued and sustained efforts are needed to develop control tools through research and development in partnership.

Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186